RxDoctor Payments DataLook up a doctor →

Scott Lunin, MD

Medical Oncology · Sarasota, FLNPI 1003807645

Payments from drug & device makers

$3,001,693in general payments, 2019–2025

Across 974 payments — averaging $3081.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Beigene, Ltd.$2M
  • Janssen Research & Development, LLC$232K
  • Beone Medicines Ltd.$228K
  • Acerta Pharma LLC$177K
  • Takeda Pharmaceuticals U.S.A., Inc.$145K
  • Verastem, Inc.$50K
  • plus $152K from 54 others
$13,684in research payments, 2019–2025

Across 2 payments — averaging $6842.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acerta Pharma LLC$8K
  • Takeda Pharmaceuticals U.S.A., Inc.$6K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Beigene, Ltd.133$2,018,764
Janssen Research & Development, LLC99$231,890
Beone Medicines Ltd.8$228,105
Acerta Pharma LLC10$177,340
Takeda Pharmaceuticals U.S.A., Inc.70$144,513
Verastem, Inc.84$49,526
Novartis51$31,344
Genentech, Inc.5$23,729
Aadi Bioscience, Inc.9$23,026
Beigene AUS Pty Ltd12$22,272
Incyte Corporation31$22,069
Pharmacyclics LLC, An Abbvie Company13$17,722
Merck43$1,796
Exelixis Inc.7$1,451
TG Therapeutics, Inc.2$1,125
Johnson & Johnson(2 entities)87$937
E.r. Squibb & Sons, L.L.C.44$667
Gilead(2 entities)29$553
Pfizer36$536
Bristol Myers Squibb21$508
Beigene USA, Inc.7$496
AstraZeneca(2 entities)5$294
Daiichi Sankyo Inc.11$286
GSK15$267
Array Biopharma Inc12$217
AbbVie9$206
Sanofi10$199
Genentech USA, Inc.23$198
Astellas Pharma US Inc9$170
Lilly USA, LLC7$153
Rigel Pharmaceuticals, Inc.5$137
Taiho Oncology, Inc.7$117
Tersera Therapeutics LLC4$101
Pharmaessentia USA Corporation3$62
Seagen Inc.3$61
Sumitomo Pharma America, Inc.4$60
Jazz Pharmaceuticals Inc.3$58
Ipsen Biopharmaceuticals, Inc3$58
Amgen4$58
AVEO Pharmaceuticals, Inc.3$52
Puma Biotechnology, Inc.3$52
EMD Serono, Inc.3$44
Regeneron Healthcare Solutions, Inc.2$40
Morphosys, US Inc.2$36
Eisai Inc.2$34
Iovance Biotherapeutics, Inc.1$32
ADC Therapeutics America, Inc.2$30
Heron Therapeutics, Inc.1$25
Napo Pharmaceuticals Inc1$24
Dendreon Pharmaceuticals LLC1$24
Beone Medicines USA, Inc.1$23
EUSA Pharma (US) LLC1$23
Springworks Therapeutics, Inc.1$22
Stemline Therapeutics Inc.1$22
Geron Corporation1$21
Pharmacosmos Therapeutics Inc.1$20
Karyopharm Therapeutics Inc.1$17
G1 Therapeutics, Inc.1$15
Mirati Therapeutics, Inc.1$14
Apellis Pharmaceuticals, Inc.1$13

How this compares

$3,001,693 in reported general payments places this provider in the 90th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$6,005,721
Medicare patients
878
Services billed
300,973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Sarasota

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →